The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 54 results:
Author [ Title(Asc)] Type Year
Filters: Author is Bekiari, Eleni  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
U
Liakos, A., Karagiannis T., Bekiari E., Boura P., & Tsapas A. (2015).  Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus.. Ther Adv Endocrinol Metab. 6(2), 61-7.
Avgerinos, I., Papanastasiou G., Karagiannis T., Michailidis T., Liakos A., Mainou M., et al. (2021).  Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis.. Diabetes Obes Metab. 23(10), 2395-2401.
S
Bekiari, E., Rizava C., Athanasiadou E., Papatheodorou K., Liakos A., Karagiannis T., et al. (2016).  Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine. 458 - 480.
Avgerinos, I., Karagiannis T., Kakotrichi P., Michailidis T., Liakos A., Matthews D. R., et al. (2022).  Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis.. Diabetes Obes Metab. 24(1), 106-114.
Liakos, A., Tsapas A., & Bekiari E. (2020).  Some glucose-lowering drugs reduce risk for major adverse cardiac events.. Ann Intern Med. 173(2), JC9.
Vasilakou, D., Karagiannis T., Athanasiadou E., Mainou M., Liakos A., Bekiari E., et al. (2013).  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.. Ann Intern Med. 159(4), 262-74.
Karagiannis, T., Bekiari E., & Tsapas A. (2023).  Socioeconomic aspects of incretin-based therapy.. Diabetologia. 66(10), 1859-1868.
Tsapas, A., Liakos A., Paschos P., Karagiannis T., Bekiari E., Tentolouris N., et al. (2014).  A simple plaster for screening for diabetic neuropathy: a diagnostic test accuracy systematic review and meta-analysis.. Metabolism. 63(4), 584-92.
Mantsiou, C., Liakos A., Mainou M., Papanas N., Tsapas A., & Bekiari E. (2023).  A Simple Guide to Systematic Reviews and Meta-Analyses.. Int J Low Extrem Wounds. 15347346231169842.
Andreadis, P., Karagiannis T., Malandris K., Avgerinos I., Liakos A., Manolopoulos A., et al. (2018).  Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.. Diabetes Obes Metab. 20(9), 2255-2263.
Andreadis, P., Karagiannis T., Malandris K., Avgerinos I., Liakos A., Manolopoulos A., et al. (2018).  Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism.
R
Avgerinos, I., Karagiannis T., Liakos A., Tsapas A., & Bekiari E. (2023).  Racial, ethnic and sex disparities among participants in cardiovascular outcomes trials in type 2 diabetes: A systematic review and descriptive analysis.. Diabetes Obes Metab. 25(2), 618-622.
P
Tsapas, A., Karagiannis T., & Bekiari E. (2016).  Premixed insulin regimens for type 2 diabetes. Endocrine. 5128136293852682932172681092030295868(321Suppl 2811036512641555321), 387 - 389.
Stafylidou, M., Paschos P., Katsoula A., Malandris K., Ioakim K., Bekiari E., et al. (2019).  Performance of Baveno VI and Expanded Baveno VI Criteria for Excluding High-Risk Varices in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis.. Clin Gastroenterol Hepatol. 17(9), 1744-1755.e11.
O
Stoimenis, D., Karagiannis T., Katsoula A., Athanasiadou E., Kazakos K., Bekiari E., et al. (2017).  Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.. Expert Opin Pharmacother. 18(9), 843-851.
Stoimenis, D., Karagiannis T., Katsoula A., Athanasiadou E., Kazakos K., Bekiari E., et al. (2017).  Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy. 18555857646565(9111111), 843 - 851.
M
Karagiannis, T., & Bekiari E. (2016).  Most add-on therapies to metformin have similar effects on HbA1c.. Evid Based Med. 21(6), 223.
Karagiannis, T., Tsapas A., Bekiari E., Toulis K. A., & Nauck M. A. (2024).  A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes.. Diabetes Care. 47(2), 184-192.
Bekiari, E., Karagiannis T., Haidich A-B., & Tsapas A. (2017).  Meta-analysis of artificial pancreas trials: methodological considerations.. Lancet Diabetes Endocrinol. 5(9), 685.
Bekiari, E., Karagiannis T., Haidich A-B., & Tsapas A. (2017).  Meta-analysis of artificial pancreas trials: methodological considerations. The Lancet Diabetes & Endocrinology. 5(9), 685.
Karagiannis, T., Avgerinos I., Liakos A., Del Prato S., Matthews D. R., Tsapas A., et al. (2022).  Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.. Diabetologia. 65(8), 1251-1261.
Liakos, A., Karagiannis T., Avgerinos I., Malandris K., Tsapas A., & Bekiari E. (2023).  Management of type 2 diabetes in the new era.. Hormones (Athens). 22(4), 677-684.
K
Karagiannis, T., Tsapas A., & Bekiari E. (2021).  KDIGO made 12 recommendations for managing diabetes with CKD.. Ann Intern Med. 174(3), JC26.
I
Bekiari, E., Karagiannis T., & Tsapas A. (2018).  In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.. Ann Intern Med. 168(8), JC46.
Bekiari, E., Karagiannis T., & Tsapas A. (2018).  In type 2 diabetes, weekly semaglutide reduced HbA 1c and increased weight loss more than weekly exenatide ER. Annals of Internal Medicine. 168(8), JC46.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.